RCT | Efficacy and safety of topical hypericin photodynamic therapy for early-stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides).
28 Jul, 2022 | 13:09h | UTCEfficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial – JAMA Dermatology (free for a limited period)
Commentary on Twitter
The findings of this randomized clinical trial indicate that synthetic hypericin photodynamic therapy is effective in early-stage patch and plaque mycosis fungoides−cutaneous T-cell lymphoma and has a favorable safety profile. https://t.co/hHfDESptQF
— JAMA Dermatology (@JAMADerm) July 21, 2022